Legal & General Group
AKTS

Legal & General Group’s Aktis Oncology AKTS Stock Holding History

Legal & General Group’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.6K Buy
2,062
+236
+13% +$4.85K ﹤0.01% 2695
2026
Q1 		$32.7K Buy
+1,826
New +$35.5K ﹤0.01% 2801

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Legal & General Group's AKTS Position: Q2 2026 in Review

Legal & General Group increased its Aktis Oncology (AKTS) stake by 13% in Q2 2026, buying an estimated $4.85K and bringing the position to 2,062 shares worth $66.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

Legal & General Group first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Legal & General Group held 2,062 shares of Aktis Oncology worth $66.6K as of Q2 2026.
  • Legal & General Group bought 236 Aktis Oncology shares in Q2 2026, an estimated $4.85K.
  • Aktis Oncology made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2695 holding.
  • Legal & General Group first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.